Great excitement greeted the discovery a few years ago that certain cells from mice and humans could be reprogrammed to become inducible pluripotent stem cells (iPS cells) as they hold promise for cell replacement therapy and modeling human disease. Two independent research groups have now shown that both possibilities are true for iPS cell-derived liver cells known as hepatocytes.